Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel

Man, Ya-Nan; Chen, Yanfang

doi:10.1007/s11255-019-02265-4

Cited by 45 publications

(63 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No available studies were obtained from the Cochrane Library database. A total of 14 studies (11 full-text studies and 3 conference abstracts) were finally included in the present metaanalysis [9,12,13,[14][15][16][17][18][19][20][21][22][23][24]. Figure 1 shows the study selection process.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Huang

Gao

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background Several studies have reported that the systemic immune-inflammation index (SII) is associated with the prognosis of patients with urologic cancers (UCs). The aim of this study was to systematically evaluate the prognostic value of SII in UC patients. Methods We searched public databases for relevant published studies on the prognostic value of SII in UC patients. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and pooled to assess the relationships between SII and overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), overall response rate (ORR) and disease control rate (DCR). Results A total of 14 studies with 3074 patients were included. From the pooled results, we found that high SII was associated with worse overall survival (OS) in patients with UC (HR 2.58, 95% CI 1.59–4.21). Patients with high SII values also had poorer PFS (HR 1.92, 95% CI 1.29–2.88) and CSS (HR 2.58, 95% CI 1.36–4.91) as well as lower ORRs (HR 0.40, 95% CI 0.22–0.71) than patients with low SII values. In addition, the subgroup analysis of OS and PFS showed that the prognosis of patients with high SII was worse than that of patients with low SII. Conclusions SII might be a promising noninvasive predictor in patients with UC. However, more samples and multicenter studies are needed to confirm the effectiveness of SII in predicting the prognosis of patients with UC.

show abstract

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Huang

Gao

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, the present study is the first meta-analysis to evaluate the prognostic and clinicopathological value of the SII in patients with breast cancer. The SII is calculated by using the following formula: neutrophil count × platelet count/lymphocyte count; the SII was developed as a prognostic factor for determining the survival outcomes of patients with various cancers in clinical practice [28][29][30][31][32][33][34]. As the SII is an index of the combination of neutrophil, platelet, and lymphocyte counts, a high SII could be attributed to the changes in the counts of these cells.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis

2020

View full text Add to dashboard Cite

Background: Although previous studies have evaluated the prognostic role of the systemic immune-inflammation index (SII) in patients with breast cancer, the results were inconsistent. Therefore, in this context, we aimed to identify the prognostic and clinicopathological value of the SII in patients with breast cancer by performing a meta-analysis. Methods: A literature search was using PubMed, Web of Science, EMBASE, and Cochrane Library databases for relevant articles, from their inception to May 12, 2020. The prognostic value of the SII in breast cancer was assessed by pooling the hazard ratios (HRs) with 95% confidence intervals (CIs). The clinical outcomes included the overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), and distant metastasis-free survival (DMFS). The methodological quality of all the included studies was evaluated using the Newcastle-Ottawa quality assessment scale. The odds ratios (ORs) with 95% CIs were combined to evaluate the correlation between the SII and clinicopathological characteristics of patients with breast cancer. Publication bias was evaluated using the Begg funnel plot and the Egger linear regression test. All statistical analyses were performed using Stata software, version 12.0 (Stata Corporation, College Station, TX, USA). A p value of < 0.05 was considered statistically significant. Results: Eight studies involving 2642 patients were included in the current meta-analysis. The combined data showed that patients with a high SII had worse OS (HR = 1.79, 95% CI 1.33-2.42, p < 0.001), poorer DFS/RFS (HR = 1.79, 95% CI 1.31-2.46, p < 0.001), and inferior DMFS (HR = 1.64, 95% CI 1.32-2.03, p < 0.001) than patients with a low SII. In addition, a high SII was correlated with the presence of lymph node metastasis (OR = 1.38, 95% CI 1.12-1.69, p = 0.002), higher T stage (OR = 1.49, 95% CI 1.17-1.89, p < 0.001), advanced TNM stage (OR = 1.37, 95% CI 1.07-1.77, p = 0.014), and higher histological grade (OR = 3.71, 95% CI 1.00-13.73, p = 0.049). However, there was no significant association between the SII and the pathological type (OR = 0.82, 95% CI 0.55-1.23, p = 0.345) or lymphatic invasion (OR = 1.30, 95% CI 0.82-2.08, p = 0.266). Conclusions: The results of our meta-analysis suggest that an elevated SII predicts poor survival outcomes and is associated with clinicopathological features that indicate tumor progression of breast cancer.

show abstract

“…Of them, six studies assessed the relationship between SII and prognosis in renal cell carcinoma (RCC) patients, [19,[22][23][24][25][26] two investigated upper tract urothelial carcinoma (UTUC), [20,27] two focused on bladder cancer (BC), [28,29] and three explored PC. [18,30,31] In terms of the research quality evaluation, the NOS score was 9 for three datasets, 8 for six datasets, 7 for one dataset, and 6 for ve datasets, demonstrating that the included articles were overall of high quality. Other more detailed features of the enrolled studies are listed in Table 1.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 97%

“…In recent years, the relation of SII with urinary system malignancies has been explored and analysed in numerous studies. [18][19][20] However, due to the various experimental regions and subjects, the results of previous studies are not entirely consistent. To the best of our knowledge, there have not been any systematic reviews or meta-analyses researching SII in urinary system tumours until now.…”

Section: Introductionmentioning

confidence: 79%

“…In patients with UTUC undergoing radical nephroureterectomy, the results of Zheng's study supported that patients with high SII before surgery might have a markedly shorter OS, PFS, and CSS than those with low SII (all p < 0.05) [20]. The ndings of Man et al and Fan et al directly proved that pretreatment SII could assist in predicting the survival of metastatic castration-resistant PC patients treated with chemotherapy in both the training and validation cohorts, which combined with other indices (prostate-speci c antigen, albumin, and brinogen) might guide clinicians in the identi cation of high-risk populations and selection of the best treatment protocols [30,18]. In 2020, Yılmaz et al found that SII as well as other parameters, such as NLR, prognostic nutritional index, and red cell distribution, were all associated with poor survival outcomes in patients with muscle-invasive bladder cancer (MIBC) in univariate analysis.…”

mentioning

confidence: 96%

See 1 more Smart Citation

Systemic Immune-Inflammation Index is a Promising Noninvasive Biomarker for Predicting the Survival of Urinary System Cancers: A Systematic Review and Meta-Analysis

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Systemic immune-inflammation index (SII) has been reported in numerous studies to effectively predict the pathological features and survival outcomes of urinary system cancers, but no agreement has been reached. The aim of this meta-analysis is to explore the prognostic significance of pretreatment SII in tumours of the urinary system.Methods: Relevant published articles were selected from Web of Science, PubMed, Embase, and the Cochrane Library up to August 30, 2020. The pooled hazard ratios (HRs), odds ratios (ORs), and standard mean differences (SMDs) with 95% confidence intervals (CIs) were computed to estimate the associations of pretreatment SII with overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), and clinicopathological parameters in urinary system cancers.Results: Overall, a total of 13 papers published from 2016 to 2020 involving 15 datasets comprising 3974 patients were finally included in our meta-analysis. From the combined data, we found that high SII prior to treatment indicated markedly worse OS (HR =1.98, 95% CI: 1.75–2.23; p < 0.001), PFS (HR: 2.08, 95% CI: 1.32–3.26, p = 0.002) with high heterogeneity (I2 = 80.8%, p < 0.001), and CSS (HR: 2.41, 95% CI: 1.73–3.35, p < 0.001). In addition, patients who have an elevated SII value before receiving treatment might have undesirable pathological characteristics, including large tumour size, poor differentiation grade, and advanced tumour stage (all p < 0.001).Conclusion: Pretreatment SII could be used as a noninvasive and promising biomarker for indicating the prognosis of patients with urinary system cancers.

show abstract

Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel

Cited by 45 publications

References 52 publications

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis

Systemic Immune-Inflammation Index is a Promising Noninvasive Biomarker for Predicting the Survival of Urinary System Cancers: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About